Evaluation of a Multiplex Assay for Estimation of HIV-1 Incidence

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Curtis, Kelly A ^a   Hanson, Debra L ^a   Kennedy, M Susan ^a   Owen, S Michele ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 66; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; PLACEBO; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOREACTIVITY; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION;

ALGORITHMS; ANTI-HIV AGENTS; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MULTIPLEX POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 84878069321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064201     Document Type: Article

References (43)

1. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, et al. (2005) Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 43: 4441-4447.
2. Chawla A, Murphy G, Donnelly C, Booth CL, Johnson M, et al. (2007) Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 45: 415-420.
3. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, et al. (2003) Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 33: 625-634.
4. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, et al. (2002) Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18: 295-307.
5. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, et al. (2003) Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 33: 349-355.
6. Schupbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, et al. (2007) Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 4: e343.
7. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, et al. (2003) Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 32: 424-428.
8. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, et al. (2003) Evaluation of a sensitive/less sensitive testing algorithm using the bioMerieux Vironostika-LS assay for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum Retroviruses 19: 481-486.
9. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, et al. (2012) Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies. PLoS One 7: e33328.
10. Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, et al. (2010) Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses 26: 61-71.
11. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, et al. (1998) New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280: 42-48.
12. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS, (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623-2628.
13. UNAIDS Reference Group on estimates, modelling and projections-statement on the use of the BED assay for the estimation of HIV-1 incidence for surveillance or epidemic monitoring. Wkly Epidemiol Rec 81: 40.
14. Sakarovitch C, Rouet F, Murphy G, Minga AK, Alioum A, et al. (2007) Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 45: 115-122.
15. Westreich D, Pettifor A, Karita E, Price M, Fiamma A, et al. (2007) Overestimation of the South African HIV incidence using the BED IgG assay? S Afr Med J 97: 476, 478; author reply 478, 480.
16. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, et al. (2011) Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265-273.
17. Hayashida T, Gatanaga H, Tanuma J, Oka S, (2008) Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 24: 495-498.
18. Killian MS, Norris PJ, Rawal BD, Lebedeva M, Hecht FM, et al. (2006) The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 22: 640-647.
19. Selleri M, Orchi N, Zaniratti MS, Bellagamba R, Corpolongo A, et al. (2007) Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr 46: 145-150.
20. Incidence Assay Critical Path Working G, (2011) More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med 8: e1001045.
21. (2011) Meeting Report: WHO Working Group on HIV Incidence Assays. Available: http://www.who.int/diagnostics_laboratory/links/who_incidence_meeting_draftreport_december2011.pdf. Accessed 14 April 2013.
22. Braunstein SL, Nash D, Kim AA, Ford K, Mwambarangwe L, et al. (2011) Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One 6: e18402.
23. Laeyendecker O, Brookmeyer R, Mullis C, Donnell D, Lingappa J, et al. (2012) Specificity of four laboratory approaches for cross-sectional HIV incidence determination: Analysis of samples from adults with known non-recent HIV infection from five African countries. AIDS Res Hum Retroviruses 28: 1177-1183.
24. Curtis KA, Kennedy MS, Charurat M, Nasidi A, Delaney K, et al. (2012) Development and characterization of a bead-based, multiplex assay for estimation of recent HIV type 1 infection. AIDS Res Hum Retroviruses 28: 188-197.
25. Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, et al. (2001) Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 183: 23-35.
26. Seage GR, 3rd, Holte SE, Metzger D, Koblin BA, Gross M, et al (2001) Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 153: 619-627.
27. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
28. Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, et al. (2004) Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 37: 1160-1165.
29. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
30. Charurat M, Nasidi A, Delaney K, Saidu A, Croxton T, et al. (2012) Characterization of Acute HIV-1 Infection in High-Risk Nigerian Populations. J Infect Dis 205: 1239-1247.
31. Kaplan JE, Spira TJ, Fishbein DB, Lynn HS, (1992) Ten-year follow-up of HIV-infected homosexual men with lymphadenopathy syndrome: evidence for continuing risk of developing AIDS. J Acquir Immune Defic Syndr 5: 565-570.
32. Kaplan JE, Spira TJ, Fishbein DB, Pinsky PF, Schonberger LB, (1987) Lymphadenopathy syndrome in homosexual men. Evidence for continuing risk of developing the acquired immunodeficiency syndrome. JAMA 257: 335-337.
33. Fishbein DB, Kaplan JE, Spira TJ, Miller B, Schonberger LB, et al. (1985) Unexplained lymphadenopathy in homosexual men. A longitudinal study. JAMA 254: 930-935.
34. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, et al. (2012) Initial HIV- 1 Antigen-specific CD8+ T cells In Acute HIV-1 Inhibit Transmitted Founder Virus Replication. J Virol 86: 6835-6846.
35. Motulsky H, Christopoulos A (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting. USA: Oxford University Press. 352 p.
36. Findlay JW, Dillard RF, (2007) Appropriate calibration curve fitting in ligand binding assays. AAPS J 9: E260-267.
37. Davidian M, Giltinan DM (1995) Nonlinear Models for Repeated Measurement Data. New York: Chapman & Hall/CRC. 360 p.
38. Pinheiro JC, Douglas DM, (1995) Approximations to the Loglikelihood Function in the Nonlinear Mixed Effects Model. Journal of Computational and Graphical Statistics 4: 12-35.
39. Schenker N, Taylor JMG, (1996) Partially Parametric Techniques for Multiple Imputation. Computational Statistics and Data Analysis 22: 425-446.
40. Kassanjee R, McWalter TA, Barnighausen T, Welte A, (2012) A New General Biomarker-based Incidence Estimator. Epidemiology 23: 721-728.
41. Yeh S-T (2002) Using Trapezoidal Rule for the Area Under a Curve Calculation. Available: http://www2.sas.com/proceedings/sugi27/p229-27.pdf. Accessed 17 April 2013.
42. Lee ET (1992) Statistical Methods for Survival Data Analysis. Wiley-Interscience. 534 p.
43. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, et al. (2004) Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 18: 2253-2259.